December 19, 2022
Based on current discussions by the European Commission, launch conditionalities would not account for the distinct nature of small and mid-sized companies, OMPs and ATMPs. EUCOPE’s Alexander Natz breaks down this aspect of the revision of the General Pharmaceutical Legislation… read more
October 27, 2022
In this guest blog post, Takeda’s Andre Vidal Pinheiro evaluates the value of partnerships across the medicines lifecycle and why real-world evidence (RWE) is fundamental for healthcare systems to provide better and tailored outcomes for patients. The world is moving… read more
October 12, 2022
The EU biopharmaceutical ecosystem is currently languishing in third place globally. EUCOPE’s Alexander Natz discusses how the European Commission’s most fundamental review of the pharmaceutical legislation in decades is supposed to change that but in reality, is discouraging innovation and competitiveness…. read more
September 19, 2022
The EHDS won’t only change how patients, doctors, researchers and policymakers access and use health data; it’s also hoped that the plan will lead to billions in economic gains for European life sciences. This article was originally published on Bio.news…. read more
June 30, 2022
The Covid-19 pandemic remains a dominant theme in our forward-looking view for companies in the life sciences and health care industry, as the past year has continued to create challenges and a seemingly endless stream of lockdowns and viral surges…. read more